Loading the player...
Information
Weekly Basal Insulin for Type 2 Diabetes: Safety and Efficacy of the New Emerging Products
*** Please note this program was a part of the MOA ‘s 114th Annual Convention. You will not want to choose this program if you completed this individual program as part of the MOA’s 114th Annual Convention.***
Learning Objectives:
- Describe the place of novel insulin therapies, including once-weekly basal insulin, in treating type 2 diabetes
- Identify the causes of clinical inertia in the use of basal insulin for type 2 diabetes treatment
- Examine the consequences of delaying initiation and intensification of basal insulin in eligible patients
- Develop a comprehensive treatment plan using once-weekly basal insulin, individualizing therapy to patient goals while using a shared decision-making mode
This session is accredited for a maximum of 1.0 AOA Category 1-A credits. Credits commensurate with participation in the session will be awarded.
MOA Grievance Policy: All grievances should be initially directed in writing to the MOA Executive Director by email to info@mainedo.org who will share them with the MOA's Program Committee. Grievances will receive a response within 30 days of receipt. If you do not receive a satisfactory response, you may notify the Council on Continuing Medical Education, AOA, 142 East Ontario St., Chicago, IL 60611.
Matt Gilbert, DO
Matthew Gilbert, DO, MPH is a Professor of Medicine, Director of the Endocrine Fellowship Program in the Division of Endocrinology and Diabetes at the Larner College of Medicine at The University of Vermont and the University of Vermont Health Network Director of Diabetes. A graduate of The University of New England College of Osteopathic Medicine, Biddeford, Maine in 2003, Dr. Gilbert completed his internship and residency training in internal medicine at Bassett Medical Center, Cooperstown, New York. Dr. Gilbert received his Masters in Public Health from Boston University School of Public Health in 1999 and a Bachelor of Science degree from Susquehanna University in 1998. His current research interests include the impact of diabetes treatments in older adults and quality improvement regarding the care of patients with diabetes in the inpatient and outpatient setting. Dr. Gilbert is a member of the Endocrine Society, The American Diabetes Association and The American Thyroid Association. He lives in Vermont with his wife and two children.
Matt Gilbert, DO discloses that he is a national consultant for Novo Nordisk, which is not in any way affiliated with this presentation.
Tristan Reynolds, DO
Tristan Reynolds, DO is a Mainer who earned an undergraduate degree in biology from Pennsylvania State University and attended medical school at University of New England College of Osteopathic Medicine (UNE COM). While a medical student, Tristan was awarded a one-year OMM/anatomy pre- doctoral teaching fellowship. Tristan subsequently completed a PGY1 year in OB/GYN and, realizing that it was not the right fit, left residency to pursue academia as an assistant clinical professor at UNE COM.
He taught first and second year medical students for 5 years and rose to co-course director of UNE COM’s Year 1 Osteopathic Clinical Skills, an integrated clinical skills/anatomy/OMM course. Tristan returned to residency training at Maine-Dartmouth Family Medicine Residency (MDFMR) where he was a co-chief resident. He stayed on as full time faculty at MDFMR where he does outpatient, inpatient, and obstetrics. Tristan has specific clinical interests in diagnostic reasoning, cardiology, and addiction medicine. In his spare time, he enjoys hiking, birding, home renovation, travel, and caring for his rambunctious children.
Tristan Reynolds, DO has no actual or potential conflict of interest, financial relationship/arrangement or affiliation with any entity producing, marketing, re-selling or distributing health care goods or services consumed by, or used on, patients.
